Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
180results about How to "Specific activity" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Methods for producing heterologous disulfide bond-containing polypeptides in bacterial cells
InactiveUS6083715AEfficient productionFold preciselyBacteriaUnicellular algaeMolecular biologyDisulfide bond
Disclosed are methods and compositions for producing heterologous disulfide bond containing polypeptides in bacterial cells. In preferred embodiments the methods involve co-expression of a prokaryotic disulfide isomerase, such as DsbC or DsbG and a gene encoding a recombinant eukaryotic polypeptide. Exemplary polypeptides disclosed include tissue plasminogen activator.
Owner:GENENTECH INC +1
Methods for treating neuropathy by agonist anti-trk-C monoclonal antibodies
InactiveUS7615383B2Effective prevention and treatmentMaintain good propertiesNervous disorderGenetic material ingredientsBiologic DMARDCell system
The invention concerns agonist anti-trkC monoclonal antibodies which mimic certain biological activities of NT-3, the native ligand of trkC. The invention further concerns the use of such antibodies in the prevention and / or treatment of cellular degeneration, including nerve cell damage associated with acute nervous cell system injury and chronic neurodegenerative diseases, including peripheral neuropathy.
Owner:GENENTECH INC
Agonist anti-trk-C monoclonal antibodies
InactiveUS7384632B2Effective prevention and treatmentMaintain good propertiesNervous disorderGenetic material ingredientsMonoclonal antibodyAgonist
Owner:GENENTECH INC
Factor VIII compositions and methods
InactiveUS20050100990A1Reduce gapExtended half-lifeFactor VIIPeptide/protein ingredientsHalf-lifeNucleotide
The present invention provides methods of increasing the half-life and / or specific activity of factor VIII. More specifically, the invention provides methods of increasing the half-life and / or specific activity of factor VIII by substituting one or more amino acids in the A2 domain. It further provides methods for producing such factor VIII mutants. The invention also provides polynucleotides encoding the mutant factor VIII, and methods of treating hemophilia using the polypeptides and polynucleotides of the invention.
Owner:UNIV OF MARYLAND
Carbamate compositions and methods fo rmodulating the activity of the CHK1 enzyme
Described herein are carbamate compounds. Such compounds are capable of modulating the activity of a checkpoint kinase, and described herein are methods for utilizing such modulation to treat cell proliferative disorders. Also described are pharmaceutical compositions containing such compounds. Also described are the therapeutic or prophylactic use of such compounds and compositions, and methods of treating cancer as well as other diseases associated with unwanted cellular proliferation, by administering effective amounts of such compounds in combination with anti-neoplastic agents.
Owner:AGOURON PHARMA INC
Glucoamylase variants
InactiveUS6352851B1High specific activityImprove thermal stabilityHydrolasesBiofuelsSpecific activityChemistry
The invention relates to a variant of a parent fungal glucoamylase, which exhibits improved thermal stability and / or increased specific activity using saccharide substrates.
Owner:NOVOZYMES AS
Alpha-amylase mutants
InactiveUS6440716B1Improve stabilitySpecific activityOrganic detergent compounding agentsEnzymesMutantAlpha-amylase activity
The present invention relates to a method of constructing a variant of a parent Termamyl-like alpha-amylase, which variant has alpha-amylase activity and at least one altered property as compared to the parent alpha-amylase, comprisesi) analysing the structure of the parent Termamyl-like alpha-amylase to identify at least one amino acid residue or at least one structural part of the Termamyl-like alpha-amylase structure, which amino acid residue or structural part is believed to be of relevance for altering the property of the parent Termamyl-like alpha-amylase (as evaluated on the basis of structural or functional considerations),ii) constructing a Termamyl-like alpha-amylase variant, which as compared to the parent Termamyl-like alpha-amylase, has been modified in the amino acid residue or structural part identified in i) so as to alter the property, and, optionally,iii) testing the resulting Termamyl-like alpha-amylase variant with respect to the property in question.
Owner:NOVOZYMES AS
Method and system for advanced scenario based alert generation and processing
A computer based method and system generates alerts based on the detection of an advanced scenario in a data set. The system and method may take data related to events and entities, transform the data, and apply advanced scenarios to the data to produce matches that reflect the occurrence of an advanced scenario and the behavior of interest. The advanced scenarios can be defined to cover specific product lines and services, lines of businesses, and combinations thereof. The advanced scenarios can be defined to be indicative of a behavior class, or a specific behavior which is part of a behavior class. Alerts produced by the system can be grouped, prioritized and routed such that the appropriate users are notified in a timely manner. The system and method can be applied to a variety of industries including financial and health care, and can detect both illicit and licit behaviors of interest.
Owner:MANTAS
Interferon variants with improved properties
InactiveUS20050054053A1Increase solubilityIncrease specific activitySugar derivativesPeptide/protein ingredientsCancer researchInterferon
Owner:XENCOR
Alpha -amylase mutants
InactiveUS6022724AImprove stabilitySpecific activityOrganic detergent compounding agentsBacteriaMutantAlpha-amylase
The present invention relates to a method of constructing a variant of a parent Termamyl-like alpha -amylase, which variant has alpha -amylase activity and at least one altered property as compared to the parent alpha -amylase, comprises i) analyzing the structure of the parent Termamyl-like alpha -amylase to identify at least one amino acid residue or at least one structural part of the Termamyl-like alpha -amylase structure, which amino acid residue or structural part is believed to be of relevance for altering the property of the parent Termamyl-like alpha -amylase (as evaluated on the basis of structural or functional considerations), ii) constructing a Termamyl-like alpha -amylase variant, which as compared to the parent Termamyl-like alpha -amylase, has been modified in the amino acid residue or structural part identified in i) so as to alter the property, and, optionally, iii) testing the resulting Termamyl-like alpha -amylase variant with respect to the property in question.
Owner:NOVOZYMES AS
Stable radioiodine conjugates and methods of their synthesis
InactiveUS7147856B2Low efficiencyAggregate formationPeptide/protein ingredientsRadioactive preparation carriersCarbohydrate structureSynthesis methods
Owner:IMMUNOMEDICS INC
Process for producing antibodies
InactiveUS20060269989A1High antibody activityPromote formationAnimal cellsFungiBispecific antibodyStereochemistry
Focusing on the fact that antibody molecules with one H chain are not secreted when using the “knobs-into-holes” method, the present inventors revealed that desired bispecific antibodies can be preferentially formed by first expressing the H and L chains of one arm, and then suppressing their expression, followed by expressing the H and L chains of the other arm so that first desired HL molecules (HaLa and HbLb) are constructed, and then the H chains are paired with each other (H2L2). The present invention was thus completed.
Owner:CHUGAI PHARMA CO LTD
Subtilases
ActiveUS7294499B2High activityIncrease specific activityBacteriaDetergent compounding agentsImmunologySubtilase
Owner:NOVOZYMES AS
Social network and location-based employment placement system and method
The present disclosure is directed to an online and mobile location-based system blending social, security and communication components to help persons, including youth, find employment and internship opportunities within a community. Utilizing users' social networks, geo-location, dynamic and real-time information feeds, and proprietary prediction and security technologies, the disclosed system provides a system to create validated personal profiles for job seekers and posters, to browse and search job listings, to communicate about with other users about employment opportunities. The present invention also assists job posters and organizations to communicate about available projects within their hyper-local area.
Owner:YOUNG SARAH +2
Recombinant peptide
InactiveUS7297516B2Simple and efficientHigh specific recrystallisation inhibiting activitiesFungiBacteriaRecombinant peptideAntifreeze activity
Use of a polypeptide or protein with amino acid sequence corresponding substantially to AFP-type III HPLC 12 as additive in a product for improvement of said product, said improvement residing in improved properties of modification of ice crystal growth processes influencing size and shape characteristics of ice in particular in regrowth thereby e.g. minimising potential freezing damage e.g. by preventing or inhibiting ice recrystallisation of the product upon freezing, said use occurring in a manner known per se for anti freeze peptides to obtain higher specific modification activity in particular antifreeze activity than obtainable with the same amount of Winter Flounder AFP.
Owner:GOOD HUMOR BREYERS ICE CREAM DIV OF CONOPCO
Modified pyrroloquinoline quinone (pqq) dependent glucose dehydrogenase excellent in substrate specificity
InactiveUS20070105173A1Action propertyProcess stabilityBioreactor/fermenter combinationsFungiWild typePyrroloquinoline quinone
PQQGDH having an improved substrate specificity or having an improved specific activity in an assay system using ferricyanide ion as a mediator is provided. Modified PQQGDH having the enhanced substrate specificity by introducing an amino acid mutation in a particular region of PQQGDH, and a method of enhancing the specific activity compared with a wild type in the assay system using the ferricyanide ion as the mediator by deleting, substituting, or adding one or more amino acids in an amino acid sequence of the wild type pyrroloquinoline quinone dependent glucose dehydrogenase.
Owner:TOYO TOYOBO CO LTD
Pullulanase variants and methods for preparing such variants with predetermined properties
InactiveUS6350599B1Improve propertiesAltered physicochemical propertySugar derivativesPeptide/protein ingredientsPullulanaseSubstrate specificity
The inventors have modified the amino acid sequence of a pullulanase to obtain variants with improved properties, based on the three-dimensional structure of the pullulanase Promozyme(R). The variants have altered physicochemical properties, e.g. an altered pH optimum, improved thermostability, altered substrate specificity, increased specific activity or an altered cleavage pattern.
Owner:NOVOZYMES AS
Factor VIII compositions and methods
Owner:UNIV OF MARYLAND BALTIMORE
Compositions and methods for identifying and testing TGF- beta pathway agonists and antagonists
InactiveUS6046165ASimple and sensitiveEasy to separateBiocidePeptide/protein ingredientsADAMTS ProteinsAgonist
The invention provides compositions and methods of identifying and testing TGF- beta pathway agonists and antagonists, and in particular compositions comprising Mothers against DPP (MAD) proteins and related Smad polypeptides which exhibit sequence-specific DNA-binding activity. The invention also provides a novel DNA sequence (SEQ ID NO:19); (SEQ ID NO:20); (SEQ ID NO:21) that is bound with high affinity by Drosophila MAD protein. This protein is useful for identifying compounds that will enhance or interfere with MAD protein-DNA binding.
Owner:WISCONSIN ALUMNI RES FOUND +1
Conserved Neisserial antigens
InactiveUS7368261B1Easy to useReduce complexityAntibacterial agentsPeptide/protein ingredientsAntigenSalmonella serotype typhi
To ensure maximum cross-strain recognition and reactivity, regions of proteins that are conserved between different Neisserial species, serogroups and strains can be used. The invention provides proteins which comprise stretches of amino acid sequence that are shared across the majority of Neisseria, particularly N. meningitidis and N. gonorrhoeae.
Owner:NOVARTIS AG
Inactivation resistant factor VIII related applications
InactiveUS20020132306A1Reduce the possibilityLow costOrganic active ingredientsBiocideBinding siteENCODE
The present invention provides novel purified and isolated nucleic acid sequences encoding procoagulant-active FVIII proteins. The nucleic acid sequences of the present invention encode amino acid sequences corresponding to known human FVIII sequences, wherein residue Phe3O9 is mutated. The nucleic acid sequences of the present invention also encode amino acid sequences corresponding to known human FVIII sequences, wherein the APC cleavage sites, Arg336 and Ile562, are mutated. The nucleic acid sequences of the present invention further encode amino acid sequences corresponding to known human FVIII sequences, wherein the B-domain is deleted, the von Willebrand factor binding site is deleted, a thrombin cleavage site is mutated and an amino acid sequence spacer is inserted between the A2- and A3-domains. Methods of producing the FVIII proteins of the invention, nucleotide sequences encoding such proteins, pharmaceutical compositions containing the nucleotide sequences or proteins, as well as methods of treating patients suffering from hemophilia, are also provided.
Owner:RGT UNIV OF MICHIGAN
Novel cellobiohydrolase enzymes
Provided are isolated cellobiohydrolases comprising a modified Glycoside Hydrolase (GH) Family 7 catalytic domain, a GH Family 7 catalytic domain and a modified Family 1 carbohydrate binding module (CBM), or both a modified Family 7 catalytic domain and a modified Family 1 CBM. Such isolated cellobiohydrolases exhibit from 45% to about 99.9% amino acid sequence identity to amino acids 1-436 of SEQ ID NO: 1 or to amino acids 1-438 of SEQ ID NO: 2 and improved activity on process substrates. Also provided are genetic constructs and genetically modified microbes for expressing the isolated cellobiohydrolases, a process for producing the isolated cellobiohydrolases, cellulase enzyme mixtures comprising the isolated cellobiohydrolase and a process for hydrolysing a cellulosic substrate with such cellulase enzyme mixtures.
Owner:IOGEN ENERGY CORP
Recombinant factor viii having enhanced stability following mutation at the a1-c2 domain interface
InactiveUS20120065136A1Enhance inter-domain binding affinityIncreased stability parameterFactor VIIFungiFactor iiHaemophilia A
The invention relates to a recombinant factor VIII that includes one or more mutations at an interface of A1 and C2 domains of recombinant factor VIII. The one or more mutations include substitution of one or more amino acid residues with either a cysteine or an amino acid residue having a higher hydrophobicity. This results in enhanced stability of factor VIII. Methods for making the recombinant factor VIII, pharmaceutical compositions containing the recombinant factor VIII, and use of the recombinant factor VIII for treating hemophilia A are also disclosed.
Owner:UNIVERSITY OF ROCHESTER
FSH and LH separation and purification process
InactiveUS6162905ASpecific activityHigh purityPeptide/protein ingredientsPeptide preparation methodsDepyrogenationIon exchange
A new process, particularly simple and economical, for FSH and LH separation and purification starting from crude HMG preferably urinary, comprising the following steps: 1) optional exhaustion of crude HMG viral charge in aqueous EtOH 2) ion-exchange chromatography on weakly basic anionic resins of DEAE type; 3) affinity chromatography on resin having an antraquinone derivative as a ligand; 4) optional ion-exchange chromatography on strongly basic anionic resins; Hormones obtained thereby, in particularly pure form and having high specific activity, may subsequently undergo a depyrogenation step.
Owner:ICORE INT +1
Mutated prenyl diphosphate synthases
InactiveUS6316216B1High stabilitySpecific activitySugar derivativesBacteriaAmino acid substitutionAmino acid residue
A mutant prenyl diphosphate synthase having a modified amino acid sequence of prenyl diphosphate synthase, wherein the amino acid residue located at the eighth position in the N-terminal direction from D of the N-terminal of the Asp-rich domain DDXX(XX)D (in the sequence X denotes any amino acid and the two X's in the parentheses may not be present) present in the region II has been substituted by another amino acid, or both of the amino acid residue located at the fifth position in the N-terminal direction from D of the N-terminal and the amino acid residue located at the eighth position in the N-terminal direction from D of the N-terminal have been substituted by other amino acids.
Owner:TOYOTA JIDOSHA KK
BMP-2 variants with improved properties
InactiveUS20060235204A1High expressionImprove solubilityPeptide/protein ingredientsBone-inducing factorGeneticsBioinformatics
Owner:XENCOR INC
Vip3 toxins and methods of use
Owner:SYNGENTA PARTICIPATIONS AG
Novel vip3 toxins and methods of use
Novel Vip3 toxins that are highly active against a wide range of lepidopteran insect pests are disclosed. The DNA encoding the Vip3 toxin can be used to transform various prokaryotic and eukaryotic organisms to express the Vip3 toxin. These recombinant organisms can be used to control lepidopteran insects in various environments.
Owner:SYNGENTA PARTICIPATIONS AG
Modified Coagulation Factor VIIa With Extended Half-Life
InactiveUS20090298760A1Specific activityIncrease ratingsOrganic active ingredientsHydrolasesHalf-lifeAlbumin
The present invention relates to the fields of Factor VII (FVII) and Factor VIIa (FVIIa) albumin linked polypeptides. More specifically, the invention relates to cDNA sequences coding for human Factor VII and Factor VIIa and derivatives genetically fused to a cDNA coding for human serum albumin which may be linked by oligonucleotides which code for intervening peptidic linkers such encoded derivatives exhibiting improved stability and extended functional plasma half-life, recombinant expression vectors containing such cDNA sequences, host cells transformed with such recombinant expression vectors, recombinant polypeptides and derivatives which do have biological activities of the unmodified wild type protein but having improved stability and prolonged shelf-life and processes for the manufacture of such recombinant proteins and their derivatives. The invention also covers a transfer vector for use in human gene therapy, which comprises such modified DNA sequences.
Owner:CSL BEHRING GMBH
Subtilases
InactiveUS20070015240A1Improve thermal stabilityHigh activityBacteriaSugar derivativesGeneticsBiochemistry
Owner:NOVOZYMES AS
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com